However, if you were running an R&D organization, would you use your precious resources to invest in diabetes R&D, or would you look at other important areas like cancer and rare diseases, where the need is great but the ultimate development costs are less?
from Forbes Real Time http://www.forbes.com/sites/johnlamattina/2017/07/27/diabetes-crisis-continues-to-rage-but-biopharmas-response-is-tepid/
via IFTTT
No comments:
Post a Comment